Skip to content Skip to footer
Subscribe Now
EVENTS

Evolution Summit 2027 | January 19-20 | Four Seasons Hotel Westlake Village, CA

The Evolution Summit will take place 19-20 January 2027 at the Four Seasons Hotel in Westlake Village, California. This invitation-only summit brings together senior clinical development leaders to benchmark strategies for strengthening trial execution, accelerating development timelines and navigating the evolving regulatory and technology landscape. The program covers AI implementation in clinical operations, ICH E6(R3)…
October 7, 2026

Read more

NEWS

Earendil Labs Inks $1.5B+ Research Collaboration with Genentech to Advance Bispecific Antibodies in Oncology

Shots: Earendil Labs has entered into a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology Earendil Labs will lead antibody discovery & research through early clinical development for programs targeting certain pre-agreed target combinations, while Genentech will take over global clinical development & commercialization As per the deal,…
September 24, 2026

Read more

INSIGHTS+

EMA Marketing Authorization of New Drugs in August 2026

Shots:  The European Commission (EC) approved Daybu (trofinetide) and Hopledo (modified-release levodopa/carbidopa) for neurological disorders, expanding treatment options for Rett syndrome and Parkinson’s disease, respectively.  Daybu was approved for neurobehavioral symptoms of Rett syndrome in patients aged ≥5 years, while Hopledo was approved for adults with Parkinson’s disease and moderate to severe motor fluctuations.  The…
September 15, 2026

Read more

NEWS

QurCan Therapeutics Partners with Eli Lilly to Develop Nucleic Acid Therapies for CNS and PNS Diseases

Shots: QurCan Therapeutics has entered into an exclusive research & collaboration agreement with Eli Lilly for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS) Lilly & QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicines for CNS & PNS delivery, with QurCan…
September 15, 2026

Read more

NEWS

Evotec and Plectonic Partner on Next-Generation T-Cell Engagers for Solid Tumors

Shots: Evotec and Plectonic Biotech have entered a research collaboration to explore a novel immunotherapy approach for solid tumors by combining Plectonic’s programmable Logibody technology with Evotec’s BiTco platform Plectonic’s Logibody uses multi-antigen tumor signatures to selectively activate T cells, while Evotec’s BiTco platform uses a non-blocking CD2 antibody to enhance T-cell activity, tumor killing…
September 2, 2026

Read more

NEWS

Styx Biotechnologies Partner with ZoeNCure Therapeutics to Advance ADC Development

Shots: Styx Biotechnologies has entered into a strategic agreement with ZoeNCure Therapeutics to accelerate selected Styx ADC programs toward first-in-human clinical studies for multiple solid tumor indications The collaboration gives Styx a capital-efficient path to advance selected ADC assets through coordinated preclinical, CMC, regulatory & clinical activities while preserving opportunities for global development & strategic partnering As…
September 2, 2026

Read more

EVENTS

Digi-Tech Pharma & AI 2027 | May 11-12 | London, UK

The pharmaceutical and healthcare industries are entering a new era of technology-led transformation, with artificial intelligence, machine learning, data science, informatics, and advanced data management reshaping how medicines are discovered, developed, and delivered. Against this backdrop, Digi-Tech Pharma & AI 2027 will bring together senior professionals, technology leaders, decision-makers, and innovators from the pharmaceutical, biotechnology,…
August 19, 2026

Read more

EXCLUSIVE

Oncolytics Biotech’s Next Chapter: Jared Kelly on Advancing Pelareorep Toward Approval  

Shots  Pelareorep is gaining regulatory momentum through multiple FDA interactions and Fast Track designations, providing greater clarity around potential registration pathways and shaping Oncolytics’ clinical development and partnership strategy.  REO-033 could mark a pivotal step toward registration as the randomized study in RAS-mutant MSS metastatic colorectal cancer builds on encouraging clinical data and has the potential to become…
August 17, 2026

Read more

Load more